400 Professional Drive
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
545 articles with Emergent BioSolutions
Continuing studies and news about COVID-19 around the world keeps coming in. Here’s a look.
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
Emergent continues to work with the FDA to address identified observations at Bayview facility in order to release additional batches and resume production .
Emergent said the vaccine candidate against the mosquito-borne illness showed an increase in immune response as measured by anti-chikungunya virus SNA.
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed.
The House Select Subcommittee on the Coronavirus Crisis questioned executives from Emergent BioSolutions as part of a congressional probe.
Emergent company executives Fuad El-ibri and Robert Kramer will be testifying before a congressional probe after a botched batch of 15 million doses of J&J’s COVID-19 vaccine.
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
Emergent BioSolutions Inc. announced that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT.
Emergent BioSolutions Inc. announced that members of the company’s senior management team will participate in the following investor conferences:.
Please check out the biopharma industry's COVID-19 stories that are trending for May 4, 2021.
Battered by vaccine manufacturing mishaps that led to the contamination of 15 million doses of the Johnson & Johnson vaccine, Emergent BioSolutions is shaking up its leadership to ensure such errors do not occur again.
Emergent BioSolutions Inc. reported financial results for the quarter ended March 31, 2021.
Statement from Health Canada on AstraZeneca and Janssen COVID-19 vaccines produced at Emergent BioSolutions
Health Canada is aware of the U.S. Food and Drug Administration's recent inspection of the Emergent BioSolutions facility in Baltimore, Maryland, which noted multiple areas of concern.
The U.S. Food and Drug Administration has completed its inspection of Emergent BioSolutions’ Baltimore-Bayview facility and provided specific feedback.
The U.S. FDA has requested that Emergent BioSolutions temporarily pause production of ingredients for the Johnson & Johnson COVID-19 vaccine at their facility in Baltimore.
Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial results for the first quarter of 2021, recent business developments, revenue guidance for the second quarter of 2021, and financial outlook for full year 2021.
Please check out the biopharma industry's COVID-19 stories that are trending for April 6, 2021.
Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the US Department of HHS to Support the Opportunity for Further Expansion of Manufacturing Capacity for J&J’s COVID-19 Vaccine
Emergent BioSolutions Inc. announced that the Company continues to be on track with its manufacturing agreements related to COVID-19 vaccines and confirmed that there are no changes to its financial guidance for 2021.
4/5/2021It was a busy week for clinical trial news. Here’s a look.
In order to have full control of J&J’s product, the production of the AstraZeneca vaccine, which was being conducted at the same facility, will move elsewhere.
Gaithersburg, Md.-based Emergent BioSolutions offered an update on its Phase III trial of SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) to treat hospitalized patients with COVID-19.